Heme Iron-Polypeptide (HIP) for Iron Deficiency Anemia
Heme iron-polypeptide is NOT recommended as a first-line oral iron supplement for treating iron deficiency anemia—standard ferrous sulfate or other non-heme iron salts should be used instead, as HIP has shown inferior efficacy in multiple clinical trials and costs 7-fold more.
Dosing and Administration (When Used)
The FDA-approved dosing for heme iron-polypeptide is:
- One capsule daily (containing 150 mg elemental iron as polysaccharide iron) 1
- Should not exceed recommended dosage 1
- May be taken with meals to minimize gastrointestinal discomfort 1
Critical caveat: Do not take within 2 hours of tetracycline antibiotics due to absorption interference 1
Why HIP Is Not Preferred: The Evidence
Inferior Efficacy in Key Populations
The most compelling evidence against HIP comes from a 2018 randomized controlled trial in post-bariatric surgery patients 2. This study was stopped early due to clear differences between groups:
Ferrous sulfate (195 mg/day) successfully normalized all iron parameters:
- Hemoglobin: 10.8 → 13.0 g/dL (p<0.0001)
- Ferritin: 4.9 → 15.5 μg/L (p<0.0001)
- Soluble transferrin receptor improved significantly
HIP (31.5-94.5 mg/day) showed no improvement in any iron status biomarker (all p>0.05) despite >94% compliance 2
This is particularly damaging to HIP's case because the theoretical advantage of heme iron is its alternative absorption pathway—yet even in malabsorptive states where this should matter most, it failed.
Additional Negative Evidence
A 2012 randomized trial in peritoneal dialysis patients found 3:
- No difference in transferrin saturation between HIP and ferrous sulfate
- Significantly lower ferritin levels with HIP (p=0.003)
- 7-fold higher cost for HIP
- Authors concluded HIP "is unlikely to have a significant role in iron supplementation"
A 2013 trial in non-dialysis CKD patients showed HIP was equivalent to IV iron sucrose for hemoglobin but achieved significantly lower ferritin levels (85.5 vs 244 μg/L, p=0.004) 4, suggesting inadequate iron store repletion.
One Positive Finding (But Not Clinically Decisive)
A 2025 trial in Gambian children found no difference in the primary endpoints (hemoglobin and ferritin) but HIP showed superiority in 5 secondary iron status measures including serum iron concentration (+48.4%) and transferrin saturation (+52.3%) 5. However, this did not translate to better anemia correction or clinical outcomes.
Guideline-Based Approach to Oral Iron
The 2024 AGA Clinical Practice Update provides the framework 6:
Start with standard oral iron (ferrous sulfate, ferrous gluconate, or ferrous fumarate)
- Historical dose: 150-200 mg elemental iron daily
- Lower or alternate-day dosing may improve tolerability and absorption 7
Add vitamin C to improve absorption 6
Expect response within 1 month—if not seen, assess for:
- Non-adherence due to side effects
- Malabsorption
- Ongoing blood loss 7
Switch to IV iron if 6:
- Patient does not tolerate oral iron
- Ferritin levels do not improve with oral trial
- Condition precludes oral absorption (IBD with active inflammation, post-bariatric surgery, celiac disease)
Common Pitfalls
- Assuming heme iron is automatically better tolerated: While theoretically less constipating, clinical trials show no consistent advantage in adverse events 3, 4
- Using HIP in malabsorptive states: The 2018 bariatric surgery trial definitively shows this doesn't work 2
- Cost considerations: At 7-fold higher cost with inferior efficacy, HIP represents poor value 3
When Might HIP Be Considered?
Based on the evidence, there is no clear clinical scenario where HIP should be preferred over standard ferrous salts or IV iron. The theoretical advantage of alternative absorption has not translated to clinical benefit in any well-designed trial.
If a patient fails standard oral iron, the appropriate next step per guidelines is IV iron formulations that can replace deficits in 1-2 infusions 6, not switching to HIP.